Iodocholesterol

Summary

Iodocholesterol (CHEMBL2110675) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 512.5 Da · C27H45IO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110675
Name	Iodocholesterol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	21150757
Molecular formula	C27H45IO
Molecular weight	512.5
InChIKey	FIOAEFCJGZJUPW-FTLVODPJSA-N

SMILES: C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)CI)C

IUPAC name: (3S,8S,9S,10S,13R,14S,17R)-10-(iodomethyl)-13-methyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol

Also known as: Iodocholesterol, IODOCHOLESTEROL

Parent form; salt/anhydrous children: CHEMBL2105011

Patent coverage: 31 distinct patent families (69 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).